JP2017538822A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017538822A5 JP2017538822A5 JP2017531176A JP2017531176A JP2017538822A5 JP 2017538822 A5 JP2017538822 A5 JP 2017538822A5 JP 2017531176 A JP2017531176 A JP 2017531176A JP 2017531176 A JP2017531176 A JP 2017531176A JP 2017538822 A5 JP2017538822 A5 JP 2017538822A5
- Authority
- JP
- Japan
- Prior art keywords
- amine polymer
- preform
- process according
- polymer
- swelling agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920000642 polymer Polymers 0.000 claims description 187
- 150000001412 amines Chemical class 0.000 claims description 166
- 238000000034 method Methods 0.000 claims description 121
- 230000008961 swelling Effects 0.000 claims description 76
- 239000003795 chemical substances by application Substances 0.000 claims description 66
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 57
- 239000011541 reaction mixture Substances 0.000 claims description 50
- 239000002904 solvent Substances 0.000 claims description 28
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 26
- 229910052739 hydrogen Inorganic materials 0.000 claims description 22
- 239000001257 hydrogen Substances 0.000 claims description 22
- 239000008194 pharmaceutical composition Substances 0.000 claims description 22
- 229910019142 PO4 Inorganic materials 0.000 claims description 18
- 229920006037 cross link polymer Polymers 0.000 claims description 17
- 238000004132 cross linking Methods 0.000 claims description 17
- 239000003431 cross linking reagent Substances 0.000 claims description 17
- 239000010452 phosphate Substances 0.000 claims description 17
- 239000000872 buffer Substances 0.000 claims description 16
- 239000006185 dispersion Substances 0.000 claims description 16
- 210000000813 small intestine Anatomy 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- VVJKKWFAADXIJK-UHFFFAOYSA-N Allylamine Chemical group NCC=C VVJKKWFAADXIJK-UHFFFAOYSA-N 0.000 claims description 14
- 239000005977 Ethylene Chemical group 0.000 claims description 14
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 13
- 230000003247 decreasing effect Effects 0.000 claims description 13
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical group CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 claims description 11
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims description 11
- WBWWGRHZICKQGZ-HZAMXZRMSA-N taurocholic acid Chemical class C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@@H](O)C1 WBWWGRHZICKQGZ-HZAMXZRMSA-N 0.000 claims description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 9
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 9
- 229940085991 phosphate ion Drugs 0.000 claims description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 8
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 8
- 150000002431 hydrogen Chemical class 0.000 claims description 8
- 238000003556 assay Methods 0.000 claims description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 5
- 239000012530 fluid Substances 0.000 claims description 5
- 230000002496 gastric effect Effects 0.000 claims description 5
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 4
- 230000002745 absorbent Effects 0.000 claims description 4
- 229920001577 copolymer Polymers 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 230000000717 retained effect Effects 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- CREMABGTGYGIQB-UHFFFAOYSA-N carbon carbon Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 claims description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 claims description 3
- 239000002798 polar solvent Substances 0.000 claims description 3
- RUOJZAUFBMNUDX-UHFFFAOYSA-N propylene carbonate Chemical compound CC1COC(=O)O1 RUOJZAUFBMNUDX-UHFFFAOYSA-N 0.000 claims description 3
- KNKRKFALVUDBJE-UHFFFAOYSA-N 1,2-dichloropropane Chemical compound CC(Cl)CCl KNKRKFALVUDBJE-UHFFFAOYSA-N 0.000 claims description 2
- NOWKCMXCCJGMRR-UHFFFAOYSA-N Aziridine Chemical compound C1CN1 NOWKCMXCCJGMRR-UHFFFAOYSA-N 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 claims description 2
- 150000001266 acyl halides Chemical class 0.000 claims description 2
- 150000001299 aldehydes Chemical group 0.000 claims description 2
- 150000001350 alkyl halides Chemical group 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 150000002118 epoxides Chemical class 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- 239000012948 isocyanate Substances 0.000 claims description 2
- 150000002513 isocyanates Chemical class 0.000 claims description 2
- NONOKGVFTBWRLD-UHFFFAOYSA-N isocyanatosulfanylimino(oxo)methane Chemical compound O=C=NSN=C=O NONOKGVFTBWRLD-UHFFFAOYSA-N 0.000 claims description 2
- 150000002576 ketones Chemical group 0.000 claims description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 2
- 239000012454 non-polar solvent Substances 0.000 claims description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 claims description 2
- 235000021317 phosphate Nutrition 0.000 claims 3
- -1 diallyl propyl diamine Chemical class 0.000 claims 2
- 150000002500 ions Chemical class 0.000 claims 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 claims 1
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 229920002518 Polyallylamine hydrochloride Polymers 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 238000006116 polymerization reaction Methods 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 125000001931 aliphatic group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- GJKBBHAIYHTKRL-UHFFFAOYSA-N 1,1-dichloroethane;heptane Chemical compound CC(Cl)Cl.CCCCCCC GJKBBHAIYHTKRL-UHFFFAOYSA-N 0.000 description 1
- XKMRRTOUMJRJIA-UHFFFAOYSA-N ammonia nh3 Chemical compound N.N XKMRRTOUMJRJIA-UHFFFAOYSA-N 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 150000004985 diamines Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229920000083 poly(allylamine) Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020104945A JP6921276B2 (ja) | 2014-12-10 | 2020-06-18 | 経口投与用プロトン結合ポリマー |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462090287P | 2014-12-10 | 2014-12-10 | |
| US62/090,287 | 2014-12-10 | ||
| PCT/US2015/065041 WO2016094685A1 (en) | 2014-12-10 | 2015-12-10 | Proton-binding polymers for oral administration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020104945A Division JP6921276B2 (ja) | 2014-12-10 | 2020-06-18 | 経口投与用プロトン結合ポリマー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017538822A JP2017538822A (ja) | 2017-12-28 |
| JP2017538822A5 true JP2017538822A5 (https=) | 2019-01-24 |
| JP6903576B2 JP6903576B2 (ja) | 2021-07-14 |
Family
ID=55080167
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017531176A Active JP6903576B2 (ja) | 2014-12-10 | 2015-12-10 | 経口投与用プロトン結合ポリマー |
| JP2020104945A Active JP6921276B2 (ja) | 2014-12-10 | 2020-06-18 | 経口投与用プロトン結合ポリマー |
| JP2021122260A Active JP7258087B2 (ja) | 2014-12-10 | 2021-07-27 | 経口投与用プロトン結合ポリマー |
| JP2023060573A Active JP7536343B2 (ja) | 2014-12-10 | 2023-04-04 | 経口投与用プロトン結合ポリマー |
| JP2024124273A Pending JP2024164031A (ja) | 2014-12-10 | 2024-07-31 | 経口投与用プロトン結合ポリマー |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020104945A Active JP6921276B2 (ja) | 2014-12-10 | 2020-06-18 | 経口投与用プロトン結合ポリマー |
| JP2021122260A Active JP7258087B2 (ja) | 2014-12-10 | 2021-07-27 | 経口投与用プロトン結合ポリマー |
| JP2023060573A Active JP7536343B2 (ja) | 2014-12-10 | 2023-04-04 | 経口投与用プロトン結合ポリマー |
| JP2024124273A Pending JP2024164031A (ja) | 2014-12-10 | 2024-07-31 | 経口投与用プロトン結合ポリマー |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US11311571B2 (https=) |
| EP (3) | EP3718551B1 (https=) |
| JP (5) | JP6903576B2 (https=) |
| KR (3) | KR102625115B1 (https=) |
| CN (2) | CN107428955B (https=) |
| AU (2) | AU2015360413B2 (https=) |
| BR (2) | BR122021001914B1 (https=) |
| CA (4) | CA3205149C (https=) |
| CY (2) | CY1122928T1 (https=) |
| DK (2) | DK3593808T3 (https=) |
| ES (2) | ES2857177T3 (https=) |
| HR (2) | HRP20200689T1 (https=) |
| HU (2) | HUE052736T2 (https=) |
| IL (4) | IL290729B2 (https=) |
| LT (2) | LT3229816T (https=) |
| MA (3) | MA48486B1 (https=) |
| MD (2) | MD3229816T2 (https=) |
| ME (1) | ME03783B (https=) |
| MX (3) | MX382077B (https=) |
| PL (2) | PL3229816T3 (https=) |
| PT (2) | PT3229816T (https=) |
| RS (2) | RS61409B1 (https=) |
| RU (2) | RU2713416C2 (https=) |
| SI (2) | SI3229816T1 (https=) |
| SM (2) | SMT202000225T1 (https=) |
| WO (1) | WO2016094685A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3287133T1 (sl) | 2013-06-05 | 2019-09-30 | Tricida Inc. | Polimeri, ki vežejo protone,za peroralno dajanje |
| LT3229816T (lt) | 2014-12-10 | 2020-05-25 | Tricida Inc. | Protoną prijungiantys polimerai, skirti peroraliniam įvedimui |
| WO2017193024A1 (en) * | 2016-05-06 | 2017-11-09 | Tricida, Inc. | Hcl-binding compositions for and method of treating acid-base disorders |
| BR112019013364A2 (pt) | 2016-12-28 | 2020-04-14 | Fujifilm Corp | emulsão de polímero contendo átomo de nitrogênio ou sal do mesmo, método de produção para o mesmo e método de produção para partículas |
| US10934380B1 (en) | 2017-09-25 | 2021-03-02 | Tricida, Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
| CN111225674A (zh) | 2017-10-16 | 2020-06-02 | 富士胶片株式会社 | 高磷血症治疗剂 |
| EP3703707A4 (en) * | 2017-11-03 | 2021-08-11 | Tricida, Inc. | METHOD FOR TREATMENT OF ACID-BASE DISORDER |
| IL319146A (en) | 2017-11-03 | 2025-04-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| MA51628A (fr) * | 2018-06-04 | 2021-03-17 | Tricida Inc | Méthode de traitement de troubles de l'équilibre acido-basique |
| WO2019236124A1 (en) * | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| US20240254267A1 (en) | 2021-03-01 | 2024-08-01 | Renosis, Inc. | Crosslinked poly (allylamine) polymer pharmaceutical compositions |
| SI4053179T1 (sl) | 2021-03-01 | 2026-01-30 | Renosis, Inc. | Farmacevtski sestavki iz premreženega poli(alilaminskega) polimera |
Family Cites Families (125)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH01100164A (ja) * | 1987-10-12 | 1989-04-18 | Shionogi & Co Ltd | スルファモイル−２−ベンゾフランカルボン酸誘導体 |
| US20050090553A1 (en) | 1992-06-30 | 2005-04-28 | Shapiro Howard K. | Compositions and method for treatment of chronic inflammatory diseases |
| US6444221B1 (en) | 1992-06-30 | 2002-09-03 | Howard K. Shapiro | Methods of treating chronic inflammatory diseases using carbonyl trapping agents |
| US5556619A (en) * | 1992-08-20 | 1996-09-17 | The Du Pont Merck Pharmaceutical Company | Crosslinked polymeric ammonium salts |
| CA2202397C (en) | 1994-10-17 | 2002-07-16 | Peter W. Stacpoole | Compositions comprising carbonate/bicarbonate buffered dichloroacetic acid and methods for treatment of metabolic and cardiovascular disorders |
| US5667775A (en) | 1993-08-11 | 1997-09-16 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5496545A (en) | 1993-08-11 | 1996-03-05 | Geltex Pharmaceuticals, Inc. | Phosphate-binding polymers for oral administration |
| US5648355A (en) | 1994-02-09 | 1997-07-15 | Kos Pharmaceutical, Inc. | Method of treatment of endogenous, painful gastrointestinal conditions of non-inflammatory, non-ulcerative origin |
| TW474813B (en) | 1994-06-10 | 2002-02-01 | Geltex Pharma Inc | Alkylated composition for removing bile salts from a patient |
| US20020006899A1 (en) | 1998-10-06 | 2002-01-17 | Pospisilik Andrew J. | Use of dipeptidyl peptidase IV effectors for lowering blood pressure in mammals |
| US5753706A (en) | 1996-12-16 | 1998-05-19 | Hsu; Chen Hsing | Methods for treating renal failure |
| JP3952223B2 (ja) * | 1997-05-28 | 2007-08-01 | 日東紡績株式会社 | アリルアミン重合体 |
| AUPO758297A0 (en) | 1997-06-27 | 1997-07-24 | Rowe, James Baber | Control of acidic gut syndrome |
| US6726905B1 (en) | 1997-11-05 | 2004-04-27 | Genzyme Corporation | Poly (diallylamines)-based phosphate binders |
| TR200001752T2 (tr) * | 1997-12-17 | 2000-12-21 | Merck & Co., Inc. | Entegrin reseptör antagonistleri |
| AU2682499A (en) | 1998-02-17 | 1999-08-30 | Dimitri R. Kioussis | Anion binding polymers and the use thereof |
| US6485703B1 (en) | 1998-07-31 | 2002-11-26 | The Texas A&M University System | Compositions and methods for analyte detection |
| US6271264B1 (en) | 1998-12-01 | 2001-08-07 | Geltex Pharmaceuticals, Inc. | Polymers containing spirobicyclic ammonium moieties as bile acid sequestrants |
| US6733780B1 (en) | 1999-10-19 | 2004-05-11 | Genzyme Corporation | Direct compression polymer tablet core |
| GB9927088D0 (en) | 1999-11-17 | 2000-01-12 | Secr Defence | Use of poly(diallylamine) polymers |
| AU2001241077A1 (en) | 2000-03-09 | 2001-09-17 | Hisamitsu Pharmaceutical Co. Inc. | Crosslinked anion-exchange resin or salt thereof and phosphorus adsorbent comprising the same |
| AU2001241076A1 (en) | 2000-03-09 | 2001-09-17 | Hisamitsu Pharmaceutical Co. Inc. | Crosslinked anion-exchange resin or salt thereof |
| AU2001241095A1 (en) | 2000-03-13 | 2001-09-24 | Hisamitsu Pharmaceutical Co. Inc. | Preventives and/or remedies for hyperphosphatemia |
| JP2002028737A (ja) | 2000-07-07 | 2002-01-29 | Fujitsu Ltd | プレス打ち抜き加工方法及びプレス打ち抜き加工装置 |
| BR0209133A (pt) | 2001-04-18 | 2004-06-15 | Genzyme Corp | Método para tratar gota e para reduzir os nìveis de ácido úrico n0 sangue |
| AU2002252632B2 (en) | 2001-04-18 | 2004-09-23 | Genzyme Corporation | Low salt forms of polyallylamine |
| CN1274668C (zh) | 2002-03-11 | 2006-09-13 | 诺瓦提斯公司 | 那格列奈的盐 |
| PL374948A1 (en) * | 2002-08-02 | 2005-11-14 | Tibotec Pharmaceuticals Ltd. | Broadspectrum 2-amino-benzothiazole sulfonamide hiv protease inhibitors |
| AU2004210013A1 (en) | 2003-02-10 | 2004-08-19 | Autogen Research Pty Ltd | Therapeutic molecules |
| TWI335218B (en) | 2003-02-19 | 2011-01-01 | Panion & Bf Biotech Inc | Ferric organic compounds, uses thereof and methods of making same |
| WO2004113872A2 (en) * | 2003-06-24 | 2004-12-29 | The Trustees Of Columbia University In The City Of New York | Covalent methods for immobilization of thiolated biomolecules on siliceous and metallic surfaces |
| US7449605B2 (en) | 2003-11-03 | 2008-11-11 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7608674B2 (en) * | 2003-11-03 | 2009-10-27 | Ilypsa, Inc. | Pharmaceutical compositions comprising cross-linked small molecule amine polymers |
| US7335795B2 (en) | 2004-03-22 | 2008-02-26 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7385012B2 (en) | 2003-11-03 | 2008-06-10 | Ilypsa, Inc. | Polyamine polymers |
| US7767768B2 (en) | 2003-11-03 | 2010-08-03 | Ilypsa, Inc. | Crosslinked amine polymers |
| US7459502B2 (en) | 2003-11-03 | 2008-12-02 | Ilypsa, Inc. | Pharmaceutical compositions comprising crosslinked polyamine polymers |
| WO2005065291A2 (en) | 2003-12-31 | 2005-07-21 | Genzyme Corporation | Enteric coated aliphatic amine polymer bile acid sequestrants |
| US20080248012A1 (en) | 2004-01-29 | 2008-10-09 | Keio University | Erythrocyte Function Modifying Substance |
| US8192758B2 (en) | 2004-03-30 | 2012-06-05 | Relypsa, Inc. | Ion binding compositions |
| US7429394B2 (en) | 2004-03-30 | 2008-09-30 | Relypsa, Inc. | Ion binding compositions |
| BRPI0509331B8 (pt) | 2004-03-30 | 2021-05-25 | Ilypsa Inc | uso de uma composição de ligação de sódio |
| US8282960B2 (en) | 2004-03-30 | 2012-10-09 | Relypsa, Inc. | Ion binding compositions |
| US7556799B2 (en) | 2004-03-30 | 2009-07-07 | Relypsa, Inc. | Ion binding polymers and uses thereof |
| US7854924B2 (en) | 2004-03-30 | 2010-12-21 | Relypsa, Inc. | Methods and compositions for treatment of ion imbalances |
| US8399025B2 (en) | 2004-06-04 | 2013-03-19 | Board Of Regents, The University Of Texas System | Polyamine modified particles |
| JP2008506771A (ja) | 2004-07-19 | 2008-03-06 | エヌ．ブイ．・ヌートリシア | 血糖値を調節するためのアスパルテートを使用するための調製物 |
| DE102004035808A1 (de) | 2004-07-21 | 2006-03-16 | Kasch, Helmut, Dr. | Ammoniumsalze und Ammoniumsalz-Mineralsalzchlatrate als Transport- und Wirkform für pharmazeutische-medizinische und als Phasentransfermittel für chemische Anwendungen |
| US8569277B2 (en) | 2004-08-11 | 2013-10-29 | Palo Alto Investors | Methods of treating a subject for a condition |
| US20080214440A1 (en) | 2004-10-08 | 2008-09-04 | Forbes Medi-Tech (Research), Inc. | Vasoactive intestinal polypeptide compositions |
| US20070293429A1 (en) | 2004-10-08 | 2007-12-20 | Therapei Pharmaceuticals, Inc. | Vasoactive Intestinal Polypeptide Compositions |
| US7985418B2 (en) | 2004-11-01 | 2011-07-26 | Genzyme Corporation | Aliphatic amine polymer salts for tableting |
| ITME20040015A1 (it) | 2004-12-07 | 2005-03-07 | Vincenzo Savica | Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico. |
| CA2613875C (en) | 2005-07-04 | 2018-09-25 | Ramu Krishnan | Improved drug or pharmaceutical compounds and a preparation thereof |
| NZ566743A (en) | 2005-08-18 | 2010-07-30 | Globoasia Llc | Pharmaceutical-grade ferric organic compounds, uses thereof and methods of making same |
| US8986669B2 (en) | 2005-09-02 | 2015-03-24 | Genzyme Corporation | Method for removing phosphate and polymer used therefore |
| CA2624112A1 (en) | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Methods for preparing core-shell composites having cross-linked shells and core-shell composites resulting therefrom |
| GB2446077B (en) | 2005-09-30 | 2010-10-13 | Ilypsa Inc | Methods and compositions for selectively removing potassium ion from the gastrointestinal tract of a mammal |
| WO2007038801A2 (en) | 2005-09-30 | 2007-04-05 | Ilypsa, Inc. | Monovalent cation-binding compositions comprising core-shell particles having crosslinked poly-vinylic shells, and methods of use thereof |
| CN101355953B (zh) | 2005-11-08 | 2014-07-09 | 味之素株式会社 | 麻醉苏醒促进剂 |
| EP1945196A2 (en) | 2005-11-08 | 2008-07-23 | Genzyme Corporation | Magnesium-containing polymers for hyperphosphatemia |
| ITMI20052461A1 (it) | 2005-12-22 | 2007-06-23 | Univ Degli Studi Milano | Sistemi microparticellari per la somministrazione orale di sostanze biologicamente attive |
| RU2008136081A (ru) * | 2006-02-14 | 2010-03-20 | Тева Фармасьютикл Индастриес Лтд. (Il) | Фармацевтические составы с алифатическими аминными полимерами и способы их производства |
| EP2016114A2 (en) | 2006-05-05 | 2009-01-21 | Genzyme Corporation | Amine condensation polymers as phosphate sequestrants |
| WO2008005217A2 (en) | 2006-07-05 | 2008-01-10 | Genzyme Corporation | Iron(ii)-containing treatments for hyperphosphatemia |
| AU2007275711A1 (en) | 2006-07-18 | 2008-01-24 | Genzyme Corporation | Amine dendrimers |
| WO2008016729A1 (en) | 2006-08-04 | 2008-02-07 | Nastech Pharmaceutical Company Inc. | Compositions for intranasal delivery of human insulin and uses thereof |
| CA2749074A1 (en) | 2006-09-01 | 2008-05-29 | Usv Limited | Process for the preparation of sevelamer hydrochloride and formulation thereof |
| US7964182B2 (en) | 2006-09-01 | 2011-06-21 | USV, Ltd | Pharmaceutical compositions comprising phosphate-binding polymer |
| BRPI0716066A2 (pt) | 2006-09-01 | 2013-09-17 | Genzyme Corp | composiÇço farmacÊutica, mÉtodo para tratar doenÇas, polÍmero de amina, rede polimÉrica, mÉtodo para preparar um polÍmero de amina, e, composto de amina |
| JP5427029B2 (ja) | 2006-09-06 | 2014-02-26 | スキャンポ・アーゲー | 消化管の重炭酸分泌を促進するための方法および組成物 |
| EP2066293A2 (en) | 2006-09-29 | 2009-06-10 | Genzyme Corporation | Amide dendrimer compositions |
| US8163799B2 (en) | 2006-12-14 | 2012-04-24 | Genzyme Corporation | Amido-amine polymer compositions |
| JP2010519298A (ja) | 2007-02-23 | 2010-06-03 | ゲンズイメ コーポレーション | アミンポリマー組成物 |
| US20080207766A1 (en) | 2007-02-27 | 2008-08-28 | Agi Therapeutics Research Ltd. | Methods and compositions for treating at least one upper gastrointestinal symptom |
| EP2131820A1 (en) | 2007-03-08 | 2009-12-16 | Genzyme Corporation | Sulfone polymer compositions |
| TWI445540B (zh) | 2007-04-20 | 2014-07-21 | Ajinomoto Kk | 抗低體溫組成物 |
| EP2152277A1 (en) | 2007-04-27 | 2010-02-17 | Genzyme Corporation | Amido-amine dendrimer compositions |
| WO2009005838A2 (en) | 2007-07-02 | 2009-01-08 | Cognate3 Llc | Process for the preparation of a non-corrosive base solution and methods of using same |
| BRPI0813928A2 (pt) * | 2007-07-11 | 2014-12-30 | Toray Industries | Polialilamina reticulada, composição farmacêutica, agente terapêutico ou profilático para hiperfosfatemia, método terapêutico ou profilático para hiperfosfatemia, uso da polialilamina reticulada, e, composto para terapia ou profilaxia de hiperfosfatemia |
| EP2016947A1 (en) | 2007-07-17 | 2009-01-21 | Chemo Ibérica, S.A. | Novel one step process for preparing cross-linked poly(allylamine) polymers |
| WO2009023544A2 (en) | 2007-08-10 | 2009-02-19 | Ilypsa, Inc. | Dosage unit anion-exchange polymer pharmaceutical compositions |
| US20090125433A1 (en) * | 2007-11-13 | 2009-05-14 | Franck Rene Mikulecz | Best pre-match routing (of foreign exchange orders) |
| US20090156647A1 (en) | 2007-12-12 | 2009-06-18 | Iovate T. & P. Inc. | Method for maintaining physiological pH levels during intensive physical exercise |
| WO2009078958A1 (en) | 2007-12-14 | 2009-06-25 | Genzyme Corporation | Coated pharmaceutical compositions |
| PA8807201A1 (es) | 2007-12-14 | 2009-07-23 | Genzyme Corp | Composiciones farmaceuticas |
| JP2009179724A (ja) * | 2008-01-31 | 2009-08-13 | Toray Ind Inc | 架橋ポリビニルアミン又はその酸付加塩、及びその医薬用途 |
| WO2009097127A1 (en) | 2008-01-31 | 2009-08-06 | Genzyme Corporation | Pharmaceutical compositions |
| WO2009114650A1 (en) | 2008-03-11 | 2009-09-17 | Chakshu Research, Inc. | Methods and compositions for treating inflammation and inflammation-related pathologies |
| WO2009125433A2 (en) * | 2008-04-08 | 2009-10-15 | Usv Limited | Process for preparation of amine polymer salt |
| ATE540660T1 (de) | 2008-04-11 | 2012-01-15 | Gp Investimenti S R L | Handstück für ultraschallbehandlungen von menschlichem gewebe |
| US20110142952A1 (en) | 2008-06-20 | 2011-06-16 | Harris David J | Pharmaceutical Compositions |
| DE102008030046A1 (de) | 2008-06-25 | 2009-12-31 | Ratiopharm Gmbh | Kompaktiertes Polyallylamin-Polymer |
| US20100008988A1 (en) | 2008-07-14 | 2010-01-14 | Glenmark Generics, Ltd. | Tablet compositions of amine polymers |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| US20100104527A1 (en) | 2008-08-22 | 2010-04-29 | Relypsa, Inc. | Treating hyperkalemia with crosslinked cation exchange polymers of improved physical properties |
| US8337824B2 (en) | 2008-08-22 | 2012-12-25 | Relypsa, Inc. | Linear polyol stabilized polyfluoroacrylate compositions |
| BRPI0920515B1 (pt) | 2008-09-25 | 2018-03-20 | Vive Nano, Inc. | Composição compreendendo nanopartícula de polímero e composto ativo agrícola |
| US20110268666A1 (en) | 2008-09-29 | 2011-11-03 | Yissum Research Development Company of the Research University of Jerusalem, Ltd. | Novel gastroretentive delivery system |
| WO2010059384A1 (en) | 2008-10-30 | 2010-05-27 | Janssen Pharmaceutica Nv | Process for the preparation of tri-substituted pyridine and tri-substituted pyrimidine derivatives useful as gdir agonists |
| US20100166861A1 (en) | 2008-12-29 | 2010-07-01 | Kelly Noel Lynch | Pharmaceutical formulations of sevalamer, or salts thereof, and copovidone |
| SI2384318T1 (en) * | 2008-12-31 | 2018-03-30 | Ardelyx, Inc. | MEASURES AND PROCEDURES FOR THE INHIBITION OF ANTIPORT INHIBITED BY NHE IN THE TREATMENT OF DISEASES RELATED TO STRENGTH OF FLAMMABILITY OR TRADEMARITY WITH SOLO, AND THE EMISSION OF GASTROINTESTINAL TREATMENT |
| US20110081413A1 (en) | 2009-01-22 | 2011-04-07 | Ashok Omray | Pharmaceutical Compositions Comprising Phosphate-Binding Polymer |
| CN102917699A (zh) | 2009-10-13 | 2013-02-06 | 密执安大学评议会 | 树枝状聚合物组合物和合成方法 |
| ES2720869T3 (es) | 2009-10-22 | 2019-07-25 | Synthon Bv | Composiciones farmacéuticas de sevelámero |
| JP5984675B2 (ja) | 2009-12-07 | 2016-09-06 | アイアンウッド ファーマシューティカルズ インコーポレイテッド | 胃腸障害の療法 |
| BR112012021448A2 (pt) | 2010-02-24 | 2016-05-31 | Relypsa Inc | polímero de amina, método para tratar doença, método de remoção de sais biliares de um indivíduo animal, método para melhorar o controle glicêmico em um indivíduo, e, processo para preparar o polímero de amina. |
| WO2011106542A2 (en) * | 2010-02-24 | 2011-09-01 | Relypsa, Inc. | Crosslinked polyvrnylamine, poly all ylamine, and polyethyleneimine for use as bile acid sequestrants |
| IT1406068B1 (it) | 2010-07-22 | 2014-02-06 | Medestea Int Spa | Polidesossiribonucleotidi (pdrn) per l'impiego nel trattamento di condizioni di acidosi e composizioni a base di polidesossiribonucleotidi per il suddetto impiego |
| US20130156720A1 (en) | 2010-08-27 | 2013-06-20 | Ironwood Pharmaceuticals, Inc. | Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders |
| KR101238210B1 (ko) | 2011-06-30 | 2013-03-04 | 엘지전자 주식회사 | 이동 단말기 |
| US20130137772A1 (en) | 2011-11-29 | 2013-05-30 | Raymond J. Bergeron | Hydroxypolyamine salts |
| SG11201408521WA (en) | 2012-06-21 | 2015-01-29 | Keryx Biopharmaceuticals Inc | Use of ferric citrate in the treatment of chronic kidney disease patients |
| JP6475624B2 (ja) | 2012-10-08 | 2019-02-27 | レリプサ， インコーポレイテッド | 高血圧症及び高カリウム血症を治療するためのカリウム結合剤 |
| SI3287133T1 (sl) * | 2013-06-05 | 2019-09-30 | Tricida Inc. | Polimeri, ki vežejo protone,za peroralno dajanje |
| HK1223031A1 (zh) | 2013-11-04 | 2017-07-21 | 凯克斯生物制药公司 | 用於降低慢性肾病患者的心力衰竭的枸橼酸铁 |
| LT3229816T (lt) | 2014-12-10 | 2020-05-25 | Tricida Inc. | Protoną prijungiantys polimerai, skirti peroraliniam įvedimui |
| WO2017193024A1 (en) | 2016-05-06 | 2017-11-09 | Tricida, Inc. | Hcl-binding compositions for and method of treating acid-base disorders |
| US10934380B1 (en) | 2017-09-25 | 2021-03-02 | Tricida, Inc. | Crosslinked poly(allylamine) polymer pharmaceutical compositions |
| IL319146A (en) | 2017-11-03 | 2025-04-01 | Tricida Inc | Compositions for and method of treating acid-base disorders |
| EP3703707A4 (en) | 2017-11-03 | 2021-08-11 | Tricida, Inc. | METHOD FOR TREATMENT OF ACID-BASE DISORDER |
| MA51628A (fr) | 2018-06-04 | 2021-03-17 | Tricida Inc | Méthode de traitement de troubles de l'équilibre acido-basique |
| WO2019236639A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| WO2019236124A1 (en) | 2018-06-04 | 2019-12-12 | Tricida, Inc. | Method of treating acid-base disorders |
| US20200306209A1 (en) | 2019-03-27 | 2020-10-01 | Tricida, Inc. | Method of treating acid-base disorders |
-
2015
- 2015-12-10 LT LTEP15823049.0T patent/LT3229816T/lt unknown
- 2015-12-10 PL PL15823049T patent/PL3229816T3/pl unknown
- 2015-12-10 WO PCT/US2015/065041 patent/WO2016094685A1/en not_active Ceased
- 2015-12-10 RU RU2017124157A patent/RU2713416C2/ru active
- 2015-12-10 MD MDE20170179T patent/MD3229816T2/ro unknown
- 2015-12-10 PT PT158230490T patent/PT3229816T/pt unknown
- 2015-12-10 DK DK19191396.1T patent/DK3593808T3/da active
- 2015-12-10 SM SM20200225T patent/SMT202000225T1/it unknown
- 2015-12-10 MA MA48486A patent/MA48486B1/fr unknown
- 2015-12-10 MX MX2019014711A patent/MX382077B/es unknown
- 2015-12-10 HR HRP20200689TT patent/HRP20200689T1/hr unknown
- 2015-12-10 ES ES19191396T patent/ES2857177T3/es active Active
- 2015-12-10 SI SI201531167T patent/SI3229816T1/sl unknown
- 2015-12-10 EP EP20154562.1A patent/EP3718551B1/en active Active
- 2015-12-10 JP JP2017531176A patent/JP6903576B2/ja active Active
- 2015-12-10 US US15/533,705 patent/US11311571B2/en active Active
- 2015-12-10 CN CN201580075741.9A patent/CN107428955B/zh active Active
- 2015-12-10 HU HUE19191396A patent/HUE052736T2/hu unknown
- 2015-12-10 CA CA3205149A patent/CA3205149C/en active Active
- 2015-12-10 BR BR122021001914-2A patent/BR122021001914B1/pt active IP Right Grant
- 2015-12-10 KR KR1020177018413A patent/KR102625115B1/ko active Active
- 2015-12-10 CA CA2969238A patent/CA2969238C/en active Active
- 2015-12-10 SI SI201531470T patent/SI3593808T1/sl unknown
- 2015-12-10 BR BR112017011838-6A patent/BR112017011838B1/pt active IP Right Grant
- 2015-12-10 ME MEP-2020-85A patent/ME03783B/me unknown
- 2015-12-10 LT LTEP19191396.1T patent/LT3593808T/lt unknown
- 2015-12-10 PL PL19191396T patent/PL3593808T3/pl unknown
- 2015-12-10 MA MA053106A patent/MA53106A/fr unknown
- 2015-12-10 SM SM20200700T patent/SMT202000700T1/it unknown
- 2015-12-10 IL IL290729A patent/IL290729B2/en unknown
- 2015-12-10 PT PT191913961T patent/PT3593808T/pt unknown
- 2015-12-10 HU HUE15823049A patent/HUE049057T2/hu unknown
- 2015-12-10 CA CA3280357A patent/CA3280357A1/en active Pending
- 2015-12-10 ES ES15823049T patent/ES2787218T3/es active Active
- 2015-12-10 AU AU2015360413A patent/AU2015360413B2/en active Active
- 2015-12-10 RS RS20210136A patent/RS61409B1/sr unknown
- 2015-12-10 MX MX2017007497A patent/MX377154B/es active IP Right Grant
- 2015-12-10 CA CA3164664A patent/CA3164664C/en active Active
- 2015-12-10 MA MA41150A patent/MA41150B1/fr unknown
- 2015-12-10 EP EP19191396.1A patent/EP3593808B1/en active Active
- 2015-12-10 CN CN202111132616.0A patent/CN113855703B/zh active Active
- 2015-12-10 IL IL322207A patent/IL322207A/en unknown
- 2015-12-10 RS RS20200504A patent/RS60208B1/sr unknown
- 2015-12-10 KR KR1020267002683A patent/KR20260017508A/ko active Pending
- 2015-12-10 MD MDE20200240T patent/MD3593808T2/ro unknown
- 2015-12-10 DK DK15823049.0T patent/DK3229816T3/da active
- 2015-12-10 EP EP15823049.0A patent/EP3229816B1/en active Active
- 2015-12-10 RU RU2020102937A patent/RU2020102937A/ru unknown
- 2015-12-10 KR KR1020247000875A patent/KR102920551B1/ko active Active
-
2017
- 2017-05-22 IL IL252439A patent/IL252439B/en active IP Right Grant
- 2017-06-08 MX MX2021004558A patent/MX2021004558A/es unknown
-
2020
- 2020-04-30 CY CY20201100400T patent/CY1122928T1/el unknown
- 2020-06-18 JP JP2020104945A patent/JP6921276B2/ja active Active
- 2020-10-13 IL IL278034A patent/IL278034B/en unknown
-
2021
- 2021-02-05 HR HRP20210204TT patent/HRP20210204T1/hr unknown
- 2021-02-19 CY CY20211100141T patent/CY1124073T1/el unknown
- 2021-07-27 JP JP2021122260A patent/JP7258087B2/ja active Active
- 2021-10-06 AU AU2021245144A patent/AU2021245144B2/en active Active
-
2022
- 2022-04-19 US US17/724,105 patent/US11738041B2/en active Active
-
2023
- 2023-04-04 JP JP2023060573A patent/JP7536343B2/ja active Active
- 2023-08-28 US US18/238,665 patent/US20230405043A1/en active Pending
-
2024
- 2024-07-31 JP JP2024124273A patent/JP2024164031A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017538822A5 (https=) | ||
| RU2017124157A (ru) | Протон-связывающие полимеры для перорального введения | |
| CN100548978C (zh) | 作为m3毒蕈碱性受体拮抗剂的吡咯烷衍生物 | |
| CN106536516A (zh) | 用于制备吡啶化合物的方法 | |
| KR20100051616A (ko) | 교차결합형 폴리（알릴아민）폴리머의 제조를 위한 새로운 원스텝 방법 | |
| BRPI0717545A2 (pt) | Composição farmacêutica, método para tratar uma doença, polímero de amida, rede de polímero, e, método para preparar um polímero de amida | |
| WO2003086316A2 (en) | Degradable crosslinkers, and degradable crosslinked hydrogels comprising them | |
| DE112011100657T5 (de) | Amin-polymere zur verwendung als gallensäuresequestriermittel | |
| JPH11500161A (ja) | 高分子化合物 | |
| WO2019020580A1 (en) | PROCESS FOR PREPARING AND PURIFYING LIFITEGRAST ANTAGONIST OF LFA-1 | |
| JPH06505265A (ja) | ヒスタミンｈ↓３受容体に対する作動的または拮抗的活性を有するイミダゾール誘導体 | |
| JPH0253453B2 (https=) | ||
| JP5430812B2 (ja) | 脱除剤樹脂及びその使用方法 | |
| JP2022037143A (ja) | 終末糖化産物（ａｇｅ）前駆体の捕捉剤 | |
| CN116251226A (zh) | 一种不透射线显影栓塞微球及其制备方法 | |
| JP2009507019A (ja) | リン酸塩を除去する方法およびそれに使用される重合体 | |
| US9475891B2 (en) | Process for the preparation of colesevelam hydrochloride | |
| CN109641975A (zh) | 用于裂解酰胺键的方法 | |
| WO2024199096A1 (zh) | 一种抗凝逆转剂及其制备方法和应用 | |
| KR101853260B1 (ko) | 세벨라머 카보네이트의 제조방법 | |
| CZ2003736A3 (cs) | Způsob promývání k čištění polymerů obsahujících atom dusíku nebo aminoskupinu, amoniovou nebo spirobicyklickou amoniovou skupinu | |
| CN106632041B (zh) | 一种酒石酸左洛啡烷的制备方法 | |
| CN117285511B (zh) | 吲哚杂化的喹诺酮类化合物及其制备方法和应用 | |
| JPH08507758A (ja) | 薬理活性を有するアミド化合物 | |
| EP3727340A1 (en) | Pharmaceutical composition containing crosslinked ion exchange resin |